Evidence map›Paper›PMID 39354591›Full record

ArticleJournal of cardiothoracic surgery2024

Apatinib monotherapy for early non-small cell lung cancer: a case report.

Jiafang Xu, Qingjie Hu, Siqi Yin, Huifang He, Hai Li, Ruiqi Yang, Meizi Song, Chaoqun Wang, Yu Liu

Erratum issuedAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cardiothoracic surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Jiafang Xu *Reproductive Medicine Center, The First Affiliated Hospital of Hainan Medical University, Haikou, 570102, China.
Qingjie Hu *Department of Breast Surgery, The First Affiliated Hospital of Hainan Medical University, Haikou, 570102, China.
Siqi YinDepartment of Breast Surgery, The First Affiliated Hospital of Hainan Medical University, Haikou, 570102, China.
Huifang HeDepartment of Breast Surgery, The First Affiliated Hospital of Hainan Medical University, Haikou, 570102, China.
Hai LiDepartment of Breast Surgery, The First Affiliated Hospital of Hainan Medical University, Haikou, 570102, China.
Ruiqi YangDepartment of Nuclear Medicine, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, 570311, China.
Meizi SongDepartment of Breast Surgery, The First Affiliated Hospital of Hainan Medical University, Haikou, 570102, China.
Chaoqun WangDepartment of Nuclear Medicine, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, 570311, China. hyxwangcq@163.com.
Yu LiuDepartment of Breast Surgery, The First Affiliated Hospital of Hainan Medical University, Haikou, 570102, China. 15218046@qq.com.

Funding

Hainan Provincial Department of Health WSJK2024MS197Key Research and Development Project of Hainan Province ZDYF2020139
6 · The paper itself

Abstract

Stage I non-small cell lung cancer (NSCLC) accounts for about 15% of incident cancer cases. Prognosis is poor, with a metastasis and recurrence rate of 38% within 2 years of surgery and an overall 5-year survival rate of 54-60%. Here, we report successful apatinib monotherapy of early NSCLC in a patient who had declined surgery, radiofrequency ablation, and immunotherapy. The patient received apatinib for 64 months without clinical, laboratory, or radiographic evidence of disease progression. The curative effect was judged to be stable and safe.The role of apatinib as monotherapy for patients with early stage NSCLC who are not candidates for surgery or radiotherapy, or as an adjunct to standard therapy, deserves further study.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsPyridinesAgedAntineoplastic AgentsHumansMaleMiddle AgedNeoplasm StagingAntineoplastic AgentsapatinibPyridinesApatinibNon-small cell lung cancerSafety of ApatinibTargeted therapyVEGFR

Identifiers

PMID39354591
PMCPMC11443888

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.